60
Views
20
CrossRef citations to date
0
Altmetric
Article

New Regulatory Roles of Galectin-3 in High-Affinity IgE Receptor Signaling

, , , , , , , , , & show all
Pages 1366-1382 | Received 26 Jan 2016, Accepted 16 Feb 2016, Published online: 17 Mar 2023
 

Abstract

Aggregation of the high-affinity receptor for IgE (FcεRI) in mast cells initiates activation events that lead to degranulation and release of inflammatory mediators. To better understand the signaling pathways and genes involved in mast cell activation, we developed a high-throughput mast cell degranulation assay suitable for RNA interference experiments using lentivirus-based short hairpin RNA (shRNA) delivery. We tested 432 shRNAs specific for 144 selected genes for effects on FcεRI-mediated mast cell degranulation and identified 15 potential regulators. In further studies, we focused on galectin-3 (Gal3), identified in this study as a negative regulator of mast cell degranulation. FcεRI-activated cells with Gal3 knockdown exhibited upregulated tyrosine phosphorylation of spleen tyrosine kinase and several other signal transduction molecules and enhanced calcium response. We show that Gal3 promotes internalization of IgE-FcεRI complexes; this may be related to our finding that Gal3 is a positive regulator of FcεRI ubiquitination. Furthermore, we found that Gal3 facilitates mast cell adhesion and motility on fibronectin but negatively regulates antigen-induced chemotaxis. The combined data indicate that Gal3 is involved in both positive and negative regulation of FcεRI-mediated signaling events in mast cells.

Supplemental material for this article may be found at http://dx.doi.org/10.1128/MCB.00064-16.

ACKNOWLEDGMENTS

We thank H. Mrazova for technical assistance.

This work was supported by project P302/12/G101 from the Czech Science Foundation. M.B. and I.P. were supported in part by the Faculty of Science, Charles University, Prague. R.J.X. was supported by the Helmsley Charitable Trust, CCFA, and National Institutes of Health (DK43351).

We report no conflicting financial interests.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.